Switzerland· 57144002
Somavert 10 mg, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
A pegvisomant product containing pegvisomantum, registered in Switzerland by Pfizer AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Pegvisomant is registered in 14 of 19 countries.
Countries holding a registration under ATC H01AX01 (pegvisomant), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Pegvisomant · ATC H01AX01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of pegvisomant costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- Switzerland: $81.23 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Pegvisomant · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$81.23
- ES Spain$77.80
The record
At a glance
Swissmedic (Switzerland)- Active substance
- pegvisomantum
- Manufacturer
- Pfizer AG
- Country
- Switzerland (CH)
- ATC code
- H01AX01
- ATC class
- Pegvisomant
- Defined daily dose
- 10 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768057144002830 StkCHF 1652.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
87 interactions on record for pegvisomant.
Graded by severity as the source publishes them — 87 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pegvisomant · interactions on record
87 records
- 87 moderate
Most severe, free to view
- OpiumA07DA02moderate
- LiraglutidA08AX02moderate
- SemaglutidA08AX03moderate
- Insulin (human)A10AB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pegvisomant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSOMAVERTPfizer Europe MA EEIG, Bruxelles
- SpainSOMAVERT 10 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEPfizer Europe Ma Eeig
- BelgiumSomavert 10 mgPfizer Europe MA
- CanadaSOMAVERTPFIZER CANADA ULC
- NorwaySomavertPfizer Europe MA EEIG (1)
- PolandSomavertPfizer Europe MA EEIG
- SwedenSOMAVERT 10 mg Pulver och vätska till injektionsvätska, lösningPfizer Europe MA EEIG
- FinlandSomavertPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Somavert
- Liechtenstein · Somavert
- Norway · Somavert
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d7903adb-1352-4749-af5f-444ca0dc4241 GET /v1/drugs/d7903adb-1352-4749-af5f-444ca0dc4241?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "pegvisomantum 10 mg",
"valid_from": "2020-10-01",
"limitations": "[{\"description\":\"SOMAVERT ist indiziert zur Behandlung der Akromegalie bei Patienten, bei denen eine Operation und/oder eine Strahlentherapie und andere medizinische Therapien (Somatostatin-Analoga) nicht den gewünschten Behandlungserfolg erzielten bzw. bei denen keine dieser Therapien adäquat ist (second line).<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2022-07-01\"}]",
"galenic_form": "Trockensub 10 mg c Solv Durchstf",
"therapeutic_area": null,
"sl_inclusion_date": "2005-12-01",
"self_retention_pct": 10
}See everything about pegvisomant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.